Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.51 |
| ▸ | IL1B | P01584 | 4/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6820366 | 0.93 | HCRTR1 (0.59) | HCRTR1HCRTR2IL1BP2RX7KDM4E | |
| SCHEMBL1572370 | 0.82 | HCRTR1 (0.42) | HCRTR1HCRTR2IL1BP2RX7KDM4E | |
| SCHEMBL1339577 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2IL1BP2RX7KDM4E | |
| SCHEMBL2930345 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2IL1BP2RX7KDM4E | |
| SCHEMBL2930343 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2IL1BP2RX7KDM4E | |
| SCHEMBL1398678 | 0.81 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL983914 | 0.79 | HCRTR1 (0.43) | HCRTR1HCRTR2IL1BP2RX7KDM4E | |
| SCHEMBL1398816 | 0.78 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL1398628 | 0.78 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL1398698 | 0.78 | HCRTR1 (0.60) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885IL1B 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.